## Endosome and Golgi-associated degradation (EGAD) of membrane proteins regulates sphingolipid metabolism

Oliver Schmidt<sup>1</sup>, Yannick Weyer<sup>1</sup>, Verena Baumann<sup>1,2</sup>, Michael A. Widerin<sup>1</sup>, Sebastian Eising<sup>3</sup>, Mihaela Angelova<sup>4</sup>, Alexander Schleiffer<sup>5,6</sup>, Leopold Kremser<sup>7</sup>, Herbert Lindner<sup>7</sup>, Matthias Peter<sup>8</sup>, Florian Fröhlich<sup>3</sup>, and David Teis<sup>1\*</sup>

## **Abstract**

Cellular homeostasis requires the ubiquitin-dependent degradation of membrane proteins. This was assumed to be mediated exclusively either by endoplasmic reticulum associated degradation (ERAD) or by endosomal sorting complexes required for transport (ESCRT)dependent lysosomal degradation. We identified in Saccharomyces cerevisiae an additional pathway that selectively extracts membrane proteins at Golgi and endosomes for degradation by cytosolic proteasomes [1]. One endogenous substrate of this endosome and Golgi-associated degradation pathway (EGAD) is the ER-resident membrane protein Orm2, a negative regulator of serine-palmitoyl transferase activity and hence sphingolipid biosynthesis. Orm2 degradation is initiated by phosphorylation via the target of repamycin complex 2 and its downstream kinases Ypk1/2, which triggers its ER export. Once on Golgi and endosomes, Orm2 is poly-ubiquitinated by the membraneembedded 'Defective in SREBP cleavage' (Dsc) ubiquitin ligase complex. Cdc48/VCP then extracts ubiquitinated Orm2 from membranes, which is tightly coupled to its proteasomal degradation. Defective EGAD causes aberrant intracellular Orm2 accumulation, which disrupts sphingolipid homeostasis. Thus, the selective degradation of membrane proteins by EGAD maintains proteostasis and lipid homeostasis in eukaryotic cells.

[1] Schmidt, O. et al. (2019) **Endosome and Golgi-associated degradation (EGAD) of membrane proteins regulates sphingolipid metabolism.** *EMBO J.* (in revision)

<sup>&</sup>lt;sup>1</sup> Division of Cell Biology, Biocenter, Medical University of Innsbruck, Austria

<sup>&</sup>lt;sup>2</sup> current address: MFPL, University of Vienna, Austria

<sup>&</sup>lt;sup>3</sup> Department of Biology/Chemistry, University of Osnabrück, Germany

<sup>&</sup>lt;sup>4</sup> INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, France

<sup>&</sup>lt;sup>5</sup> Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.

<sup>&</sup>lt;sup>6</sup>Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna Biocenter (VBC), Vienna, Austria.

<sup>&</sup>lt;sup>7</sup> Division of Clinical Biochemistry, ProteinMicroAnalysis Facility, Biocenter, Medical University of Innsbruck, Austria

<sup>&</sup>lt;sup>8</sup> Institute of Biochemistry, ETH-Zürich, Switzerland

<sup>\*</sup> Corresponding author: david.teis@i-med.ac.at